Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.

ABSTRACT:

Purpose

Minimal residual disease (MRD) presents a significant hurdle to curing metastatic neuroblastoma. Biological therapies directed against MRD can improve outcome. Evaluating treatment efficacy requires MRD measurement, which serves as surrogate endpoint. Because of tumor heterogeneity, no single marker will likely be adequate. Genome-wide expression profiling can uncover potential MRD markers differentially expressed in tumors over normal marrow/blood.

Experimental design

Gene expression array was carried out on 48 stage 4 tumors and 9 remission marrows using the Affymetrix U95 gene chip. Thirty-four genes with a tumor-to-marrow expression ratio higher than tyrosine hydroxylase were identified. Quantitative reverse transcription-PCR was done on all 34 genes to study the

SUBMITTER: Cheung IY 

PROVIDER: S-EPMC2670609 | biostudies-literature | 2008 Nov

REPOSITORIES: biostudies-literature